-
February 19, 2013
New draft guidance from NICE recommends that the NHS should use one test, Oncotype DX, to guide decisions about the use of chemotherapy in people with early breast cancer, but not three others.
Full story
-
December 09, 2012
Blood cancer specialists have heralded data on Pharmacyclics' ibrutinib, which is partnered with Johnson & Johnson, saying it could significantly change the treatment of chronic lymphocytic leukaemia
Full story
-
June 12, 2012
Indonesian prices of branded drugs to treat NSCLC are rising 10% a year and cost almost three times as much as generics, in a market that is set to soar in value from $16 million in 2010 to $26 million in 2015, says a new report.
Full story
-
January 26, 2012
NICE has issued final guidance not recommending the use of Roche's Avastin, Merck Serono's Erbitux or Amgen's Vectibix for the treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy.
Full story
-
January 26, 2012
NICE has issued final guidance recommending Roche's MabThera as an option when used in combination with a wide range of chemotherapy treatments for advanced follicular lymphoma.
Full story
-
January 19, 2012
Roche's Avastin is now EU-approved for use in advanced ovarian cancer. Patients in England can receive it through application to the Cancer Drugs Fund, while clinicians in Scotland, Wales and Northern Ireland can make individual funding requests for it.
Full story
-
December 13, 2011
58.4% of patients with lung cancer in England and Wales and 63.9% in Scotland received an anti-cancer treatment in 2010, compared to 54% and 64.1% respectively in 2008, say new government figures.
Full story
-
December 01, 2011
New draft guidance from NICE is good news for Roche's MabThera but not for Novartis' Gilenya.
Full story
-
September 13, 2011
Final draft guidance from NICE now recommends the use of Takeda's Mepact (mifamurtide) when it is made available at reduced cost to the NHS under a Patient Access Scheme (PAS).
Full story
-
September 06, 2011
New draft guidance from NICE recommends the use of Roche's MabThera (rituximab) in combination with a wide range of chemotherapy treatments for symptomatic stage III and IV follicular lymphoma.
Full story